Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Clinical Efficacy of Carrelizumab, Apatinib Mesylate, Albumin Paclitaxel Combined With Oxaliplatin and S-1 in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes--A Prospective, Multi-center, Randomized Controlled Study

To evaluate the clinical efficacy of camrelizumab, apatinib Mesylate and nab-paclitaxel combined with oxplatin and S-1 in the neoadjuvant treatment of locally advanced gastric cancer with different genotypes

Study Overview

• Status: Not yet recruiting
• Conditions: Locally Advanced Gastric Cancer
• Intervention / Treatment: Drug: Camrelizumab; Drug: Oxaliplatin; Drug: S1; Drug: Apatinib Mesylate; Drug: Nab paclitaxel

• Study Type: Interventional
• Enrollment (Anticipated): 203
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Chang-Ming Huang, PhD; Phone Number: 8613805069676; Email: hcmlr2002@163.com
• Study Contact Backup: Name: Hualong Zheng, PhD; Phone Number: 18359190587; Email: 291167038@qq.com

Study Locations

• China
  • Fujian
    • Fuzhou, Fujian, China, 350001
      • Fujian Medical University Union Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age from 18 to 75 years, all sex；
2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by histology or cytology；
3. CT/MRI,PET-CT or laparoscopic exploration were used to confirm the diagnosis of gastric cancer staging as cT2-4a and/or N+ and M0 before operation.；
4. measurable lesions at least should be detected by CT/MRI examination in accordance with the RECIST1.1.（CT scan of tumor lesion length≥10mm，CT scan short diameter of lymph node≥15mm，scan slice thickness 5mm）;
5. ECOG（Eastern Cooperative Oncology Group）PS（Performance Status）:0-1 scores;
6. the expected survival time is more than 12 weeks;

7. the main organ function is normal, which should meet the following criteria: （1）(1)blood routine examination standards should be met（no blood transfusion within 14 days）

   1. HB≥100g/L，
   2. WBC≥3×109/L
   3. ANC≥1.5×109/L，
   4. PLT≥100×109/L； （2）biochemical examination shall comply with the following criteria：
   1. BIL <1.5normal upper limit（ULN），
   2. ALT和AST<2.5ULN，GPT≤1.5×ULN；
   3. serum Cr≤1ULN，creatinine clearance rate>60ml/min（Cockcroft-Gault formula）
8. women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate contraception during the study period and the last 8 weeks after giving drug; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug.；
9. No other clinical studies were conducted before and during the treatment； participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up.

Exclusion Criteria:

1. Previous history of chemotherapy, radiotherapy, targeted drug therapy or immunotherapy
2. Patients with contraindications for surgical treatment and chemotherapy or whose physical condition and organ function do not allow for major abdominal surgery；
3. patients with metastasis；
4. Having any active autoimmune diseases or a history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); Patients with vitiligo or cured childhood asthma/allergies who did not need any intervention in adulthood were excluded; Autoimmune hypothyroidism treated with a stable dose of thyroid replacement hormone; Type 1 diabetes with stable doses of insulin；
5. A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation and allogeneic bone marrow transplantation；
6. Accompanied by serious heart, lung, liver, kidney disease; Have nerve, mental disease; Jaundice or obstruction of the digestive tract with severe infection；
7. pregnant or lactating women；
8. The blood pressure of patients with hypertension cannot be reduced to the normal range by the antihypertensive drugs (systolic pressure >140 mmHg, diastolic pressure >90 mmHg)；
9. With Ⅰ magnitude of coronary heart disease, arrhythmia (including QTc protracted between male > 450 ms, women > 470 ms) and cardiac insufficiency；
10. Patients have a clear tendency with gastrointestinal bleeding, including the following situation: local active ulcerative lesions, and fecal occult blood (+ +); with melena and hematemesis history in 2 months; and patients with fecal occult blood (+) and coagulation dysfunction (INR(international normalized ratio)>1.5, APTT(activated partial thromboplastin time)>1.5 ULN), with bleeding tendency;；
11. Subjects have failed to control good cardiovascular clinical symptoms or disease, including but not limited to: such as: (1) the NYHA class II heart failure or above (2) unstable angina pectoris (3) MI occurred within 1 year (4) have clinical significance of supraventricular or ventricular arrhythmias without clinical intervention on or after clinical intervention is still poorly controlled；
12. History of interstitial lung disease (except radiation pneumonia without hormone therapy), and history of non-infectious pneumonia；
13. Patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative >1.0g)；
14. A person who has previously been allergic to any component of the drug in this study； The researchers consider those who were not suitable for inclusion.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Camrelizumab combined with Oxplatin and S-1 for Immune Genotypes	Drug: Camrelizumab; Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.; Drug: Oxaliplatin; Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.; Drug: S1; S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time
Active Comparator: Oxplatin and S-1 for Immune Genotypes	Drug: Oxaliplatin; Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.; Drug: S1; S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time
Experimental: Apatinib Mesylate combined with Oxplatin and S-1 for Mesenchymal Genotypes	Drug: Oxaliplatin; Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.; Drug: S1; S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time; Drug: Apatinib Mesylate; Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday.
Active Comparator: Oxplatin and S-1 for Mesenchymal Genotypes	Drug: Oxaliplatin; Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.; Drug: S1; S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time
Experimental: Nab-paclitaxel combined with Oxplatin and S-1 for Classic Genotypes	Drug: Oxaliplatin; Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.; Drug: S1; S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time; Drug: Nab paclitaxel; nab-paclitaxel One course will last 21 days. Given twice every 3 weeks at a dose of 260 mg/m2 in day 1 and day 8.
Active Comparator: Oxplatin and S-1 for Classic Genotypes	Drug: Oxaliplatin; Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.; Drug: S1; S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time
Active Comparator: Oxplatin and S-1 for Metabolic Genotypes	Drug: Oxaliplatin; Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.; Drug: S1; S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate	Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST	4 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of postoperative hospital stay	Duration of postoperative hospital stay in days is used to assess the postoperative recovery course.	30 days
overall postoperative morbidity rates	Refers to the incidence of early postoperative complications. The early postoperative complication are defined as the event observed within 30 days after surgery.	30 days
The prediction performance of Exosome contents (including proteins, nucleic acids)	Exosomes were isolated using a Backman Optima XPN-100 instrument. The exosomes morphology was characterized using a HT7700 transmission electron microscope (Hitachi, Co. Ltd., Japan). Fluorescent spectra were recorded using a F96 Pro fluorospectrophotometer (Shanghai Lengguang Technology). The concentration and size distribution of the exosomes were quantified using nanoparticle tracking analysis (NanoSight NS 300, Malvern Instrument). The obtained results were subjected to biostatistical analysis, such as heat map generation, ROC curve establishment, and confusion matrix.	3 years
30 days mortality rates	Defined as the event observed within 30 days after surgery.	30 days
R0 resection rate	The surgical procedure was total or subtotal gastrectomy with 3 weeks after total neoadjuvant therapy.	4 months
Disease control rate		4 months
1-year and 3-year OS/DFS		1 and 3 years
adverse event	An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.	3 years

Collaborators and Investigators

• Sponsor: Fujian Medical University
• Investigators: Principal Investigator: Chang-Ming Huang, PhD, Fujian Medical University Union Hospital

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2022
• Primary Completion (Anticipated): September 1, 2024
• Study Completion (Anticipated): September 1, 2027

Study Registration Dates

• First Submitted: August 10, 2022
• First Submitted That Met QC Criteria: August 30, 2022
• First Posted (Actual): September 1, 2022

Study Record Updates

• Last Update Posted (Actual): September 1, 2022
• Last Update Submitted That Met QC Criteria: August 30, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Stomach Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Protein Kinase Inhibitors; Paclitaxel; Oxaliplatin; Apatinib
• Other Study ID Numbers: Arise-FJ-G006

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No